Are pharma mergers bad for biotech?

Off Biotech, Congress, D.C. Diagnosis, drug pricing, Human Health, legal, Life Sciences, Medicine, newsletter-dcd, policy, Science and Research, White House

You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

What is the Alzheimer’s Association actually doing to get Biogen to lower its price?

Read the rest…

Read Original Article: Are pharma mergers bad for biotech? »

About The Author